Where are the phase IIb results for Bimatoprost?

[allTheGoodNamesAreTaken]

Quel ****ing surprise.

[barfacan]

It's over fellas, close this thread. BIM is a BUST

[JayM]

Well the guy asked if they were kidding... so I thought it was best to mention that it being used for glaucoma hasn't come out the blue. So it certainly has value to the guy I wrote it to pal.

[maver1ck]

Well it is used for treating glaucoma...

Does that have any value to us?

[JayM]

Well it is used for treating glaucoma...

[Pelopeleon]

Allergan released their q2 report and there is only 1 mention of BIM and its that its starting phase 3 as a treatment for glaucoma

As a treatment for glaucoma? Are you f**** kidding me?

Well, I was waiting for some good news...

[JayM]

Joke

[maver1ck]

Allergan released their q2 report and there is only 1 mention of BIM and its that its starting phase 3 as a treatment for glaucoma

[BiqqieSmalls]

They'll most likely talk about the Kythera acquisition, the selling of its generics, and hopefully something about bimatoprost.

Poster "Biqqiesmalls" is a shareholder, and he spoke with investor relations back in May. They refused to tell him anything initially, but was promised that they'd look into it for him. He got a call 2 days later, and was told that results were not released yet, even to shareholders, the reason they haven't released results yet was because of the "complexity of bimatoprost," and that they'd release results "in a few months."

I trust the word of that representative because she looked into it for him, and called him back. So, I doubt she would lie.

I thought the selling of all its generics, including finasteride, was interesting because of their interest in commercializing set and bim. Probably of no consequence, but whatever.

I had to call them back; the woman's explanation was ambiguous. Can't wait to check the report when I head into work

[It's2014ComeOnAlready]

I hope they do mention it but I wouldn't be surprised if the recent purchase of their generics drugs department takes up most of it. I mean it was a massive deal!

They'll most likely talk about the Kythera acquisition, the selling of its generics, and hopefully something about bimatoprost.

Poster "Biqqiesmalls" is a shareholder, and he spoke with investor relations back in May. They refused to tell him anything initially, but was promised that they'd look into it for him. He got a call 2 days later, and was told that results were not released yet, even to shareholders, the reason they haven't released results yet was because of the "complexity of bimatoprost," and that they'd release results "in a few months."

I trust the word of that representative because she looked into it for him, and called him back. So, I doubt she would lie.

I thought the selling of all its generics, including finasteride, was interesting because of their interest in commercializing set and bim. Probably of no consequence, but whatever.

[JayM]

I hope they do mention it but I wouldn't be surprised if the recent purchase of their generics drugs department takes up most of it. I mean it was a massive deal!

[maver1ck]

Tomorrow is realeased some info about bimatoprost, right?

Yes. Something like 8:45 AM they release q2 report. But one member on this thread remarked that they might not release any information, and will instead wait until january when they have to divulge by law. If they dont release any information, then Im not to sure how confident I am about BIM. However, people have heard good things and maybe they are actually going to release something.

[Pelopeleon]

Tomorrow is realeased some info about bimatoprost, right?

[maver1ck]

Interesting thought - don't know if it means anything, but since Allergan sold all of its generics business to Teva, that includes generic finasteride.

Can you fill me in as to why that would mean something? Honest question

[It's2014ComeOnAlready]

Interesting thought - don't know if it means anything, but since Allergan sold all of its generics business to Teva, that includes generic finasteride.